PIII PIII
Company Profile ↓Company Overview
PIII (PIII) is a publicly traded company listed on with a market capitalization of $33.42M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 95.3%, reflecting efficient use of shareholder capital.
Revenue has grown at a 46.9% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $1.46B (-2.8% YoY); net profit $-147.95M.
- Trailing 12 Months Year-on-year growth — revenue -2.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 46.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 46.85% |
| 1 Year: | -2.76% |
Stock Price Performance
| 1 Year: | +41.45% |
| 6 Months: | +403.47% |
| 3 Months: | +251.90% |
| 1 Month: | -3.42% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)48.45 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 95.3%.
- Compounding revenue at 46.9% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 38.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 151.30M | 144.59M | 156.19M | 273.54M | 269.45M | 248.26M | 302.08M | 329.09M | 288.35M | 388.49M | 379.16M | 362.12M | - | 373.23M | 355.79M | 345.25M | 384.81M | 386.39M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 411.31M | 389.91M | 389.48M | 538.68M | 378.15M |
| Operating Income | -12.99M | -25.97M | -28.12M | -52.17M | -912.19M | -60.01M | -48.82M | -21.03M | -33.82M | -43.83M | -31.33M | -106.99M | - | -38.09M | -34.12M | -44.22M | -153.87M | 8.24M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -13.40M | -10.46M | -27.89M | -130.12M | 29.88M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.72M | 10.14M | 20.53M | 15.64M | 16.77M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -43.17M | -41.68M | -69.45M | -166.75M | -7.96M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.07M | 1.98M | 11.00K | -1.04M | -11.00M |
| Net Income | -24.65M | -29.46M | -32.05M | -10.58M | -154.35M | -11.17M | -9.20M | -9.82M | -13.30M | -18.70M | -12.02M | -46.51M | - | -20.48M | -20.36M | -31.59M | -75.52M | 1.22M |
| Diluted EPS | - | - | - | -0.25 | -3.73 | -0.27 | -0.22 | -0.09 | -0.12 | -7.86 | -7.37 | -15.70 | - | -6.28 | -6.23 | -9.67 | -23.02 | 0.32 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 145.48M | 491.06M | 578.60M | 1.05B | 1.27B | 1.50B | 1.46B |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 1.30B | 1.43B | 1.81B | 1.73B |
| Operating Income | -39.54M | -28.59M | -129.06M | -245.96M | -167.93M | -312.60M | -270.30M |
| EBITDA | - | - | - | -1.46B | -81.07M | -197.76M | -181.86M |
| Interest Expense | - | - | - | 11.40M | 15.98M | 22.17M | 55.03M |
| Pretax Income | - | - | - | -1.56B | -183.73M | -305.99M | -321.06M |
| Tax Provision | - | - | - | 1.86M | 2.69M | 4.39M | 2.02M |
| Net Income | -41.97M | -31.41M | -146.40M | -270.13M | -57.77M | -135.85M | -147.95M |
| Diluted EPS | - | - | - | -325.00 | -31.50 | -54.00 | -45.26 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 106.44M | - | 876.57M | 860.97M | 783.42M | 656.64M |
| Current Assets | - | - | - | 100.69M | 166.02M | 184.14M | 133.08M |
| Cash & Equivalents | 32.59M | 36.26M | - | 17.54M | 36.32M | 38.82M | 25.01M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 72.09M | 118.50M | 121.27M | 92.46M |
| Total Liabilities | - | 145.96M | - | 353.91M | 427.31M | 633.89M | 796.88M |
| Current Liabilities | - | 90.62M | - | 241.66M | 299.37M | 496.42M | 545.26M |
| Long Term Debt | - | 45.39M | - | 94.42M | 108.32M | 108.91M | 228.37M |
| Total Debt | - | - | - | 105.94M | 121.94M | 195.40M | 284.88M |
| Total Equity | - | - | - | 5.85M | 142.13M | 75.94M | -155.23M |
| Shares Outstanding | - | - | - | 831.58K | 2.33M | 3.26M | 3.29M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -28.29M | -24.60M | -51.13M | -126.02M | -76.03M | -110.13M | -91.24M |
| Investing Cash Flow | -3.86M | -3.17M | -8.21M | -7.73M | -1.83M | 14.53M | 129.00K |
| Financing Cash Flow | 63.62M | 34.76M | 24.79M | 11.38M | 100.33M | 98.77M | 72.81M |
| Capital Expenditure | -1.45M | -2.93M | -3.29M | -2.23M | -1.83M | - | - |
| Free Cash Flow | -29.74M | -27.52M | -54.42M | -128.25M | -77.86M | -110.13M | -91.24M |
| Net Change in Cash | - | - | - | -122.38M | 22.48M | 3.17M | -18.30M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -27.2% | -5.8% | -22.3% | -23.4% | -13.3% | -20.8% | -18.5% |
| Net Margin % | -28.8% | -6.4% | -25.3% | -25.7% | -4.6% | -9.1% | -10.1% |
| ROE % | - | - | - | -4,614.4% | -40.6% | -178.9% | 95.3% |
| ROCE % | - | -180.7% | - | -38.7% | -29.9% | -108.9% | -242.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PIII
P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call
HENDERSON, Nev., July 21, 2026--P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial resul…
P3 Health Partners (PIII) Stock Sees Fair Value Lift After Strong EBITDA And Guidance
The latest update for P3 Health Partners lifts the internal fair value reference from $10.25 to $14.00, signaling a higher price target in current analyst models. That move is tied closely to recent commentary that balances optimism about 2…
Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners
President Trump’s 12-word remark, “I don’t think about Americans’ financial situation, I don’t think about anybody,” hit the wires, and the reaction showed up in the forgotten corners of the market, where micro-cap turnarounds priced like o…
Top Midday Gainers
P3 Health Partners' (PIII) shares soared 182% amid heavy trading after the company posted overnight
P3 Health Partners Inc. Q1 2026 Earnings Call Summary
Moby summary of P3 Health Partners Inc.'s Q1 2026 earnings call
P3 Health Partners Inc (PIII) Q1 2026 Earnings Call Highlights: Surpassing Expectations and ...
P3 Health Partners Inc (PIII) reports robust Q1 performance, raises full-year outlook, and enhances balance sheet through strategic debt conversion.
PIII — Frequently Asked Questions
What is the current share price of PIII?
As of 2026-08-05 17:25 PDT, PIII trades at $10.17 on NASDAQ/NYSE. Its 52-week range is $1.52 to $16.47.
What is the market capitalisation of PIII?
PIII has a market capitalisation of $33.42M on NASDAQ/NYSE.
What is the P/E ratio of PIII?
PIII trades at a trailing price-to-earnings (P/E) ratio of -0.22. Its price-to-book (P/B) ratio is -0.22.
What is the return on equity (ROE) of PIII?
PIII has a return on equity (ROE) of 95.31%.
Is PIII a good stock to buy?
This page provides a data-driven analysis of PIII, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.